BEACON IPF: Bexotegrast as a Potential Treatment for IPF

Trial Objectives

Current treatments for idiopathic pulmonary fibrosis (IPF) are limited to antifibrotic medications that slow symptoms, but cannot stop the progression of the disease. As part of the BEACON IPF study, researchers are evaluating a new molecule called  bexotegrast, which may provide another effective way to treat IPF symptoms.

IPF causes fibrous tissue to build up in the lungs over time, reducing their normal function. This clinical trial is comparing two different doses of bexotegrast to a placebo (a medication with no active ingredient) to see if they have a positive effect on lung function over time. The goal of the trial is to determine what effects the different doses have, if they are safe, and if they cause side effects.

Participants will be randomly assigned to take one of the two study doses of the medication or the placebo medication, and will receive treatment for 52 weeks. During clinic visits, participants will be asked to complete questionnaires about their symptoms and will receive lung function testing to monitor disease progression.